Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Upgraded by Needham & Company LLC

Needham & Company LLC upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a report published on Friday, Marketbeat Ratings reports. Needham & Company LLC currently has $46.00 target price on the specialty pharmaceutical company’s stock.

Other equities analysts have also issued research reports about the stock. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. Piper Sandler restated a “neutral” rating and set a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $43.80.

Collegium Pharmaceutical Trading Down 1.3 %

NASDAQ COLL opened at $32.91 on Friday. The company has a market cap of $1.06 billion, a P/E ratio of 14.19 and a beta of 0.82. Collegium Pharmaceutical has a 12 month low of $28.39 and a 12 month high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The company has a 50-day moving average of $30.56 and a 200-day moving average of $34.07.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of COLL. TD Private Client Wealth LLC increased its holdings in Collegium Pharmaceutical by 39.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 483 shares during the last quarter. Foundry Partners LLC grew its position in shares of Collegium Pharmaceutical by 3.3% during the third quarter. Foundry Partners LLC now owns 15,781 shares of the specialty pharmaceutical company’s stock worth $610,000 after buying an additional 509 shares in the last quarter. CWM LLC grew its position in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after buying an additional 736 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares during the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in Collegium Pharmaceutical by 4.4% in the third quarter. Harbor Capital Advisors Inc. now owns 23,498 shares of the specialty pharmaceutical company’s stock valued at $908,000 after acquiring an additional 983 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.